The DOI matches its Crossref record; 87 of the 87 references it cites were found in a registry or an index.
Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma
Open accessPublished version of a preprint
Abstract
Disabling the function of immune checkpoint molecules can unlock T-cell immunity against cancer, yet despite remarkable clinical success with monoclonal antibodies (mAb) that block PD-1 or CTLA-4, resistance remains common and essentially unexplained. To date, pancreatic carcinoma is fully refractory to these antibodies. Here, using a genetically engineered mouse model of pancreatic ductal adenocarcinoma in which spontaneous immunity is minimal, we found that PD-L1 is prominent in the tumor microenvironment, a phenotype confirmed in patients; however, tumor PD-L1 was found to be independent of IFNγ in this model. Tumor T cells expressed PD-1 as prominently as T cells from chronically infected mice, but treatment with αPD-1 mAbs, with or without αCTLA-4 mAbs, failed in well-established tumors, recapitulating clinical results. Agonist αCD40 mAbs with chemotherapy induced T-cell immunity and reversed the complete resistance of pancreatic tumors to αPD-1 and αCTLA-4. The combination of αCD40/chemotherapy plus αPD-1 and/or αCTLA-4 induced regression of subcutaneous tumors, improved overall survival, and conferred curative protection from multiple tumor rechallenges, consistent with immune memory not otherwise achievable. Combinatorial treatment nearly doubled survival of mice with spontaneous pancreatic cancers, although no cures were observed. Our findings suggest that in pancreatic carcinoma, a nonimmunogenic tumor, baseline refractoriness to checkpoint inhibitors can be rescued by the priming of a T-cell response with αCD40/chemotherapy. Cancer Immunol Res; 3(4); 399–411. ©2015 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Not surprisingly, therefore, the first clinical hints of success at deploying immunotherapy in PDAC have thus come from regimens that combine chemotherapy with targeting of one or more additional nodes within the dysfunctional TME (myeloid cells, Tregs) in combination with immune checkpoint inhibitors286,287.”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [287]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
Cited by
Sorted by citations
Items 301–400 of 460
Targeted therapy for pancreatic cancer: lessons learned and future opportunities
Thomas, A. G., & Awasthi, N. (2021) · Digestive Medicine Research · doi:10.21037/dmr-21-21 · Cited by 11
Siolas, D., Morrissey, C., & Oberstein, P. E. (2020) · Journal of Pancreatology · doi:10.1097/jp9.0000000000000052 · Cited by 11
Herpels, M., Ishihara, J., & Sadanandam, A. (2023) · The Journal of Pathology · doi:10.1002/path.6171 · Cited by 11
Hydrogel-Based Therapeutics for Pancreatic Ductal Adenocarcinoma Treatment
Liu, J., Wu, W., Zhu, Q., & Zhu, H. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15102421 · Cited by 12
Lin, Y., Liang, Z., Weng, Z., Liu, X., Zhang, F., & Chong, Y. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03329-3 · Cited by 12
Winograd, R., Simeone, D. M., & Bar‐Sagi, D. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01303-2 · Cited by 11
Self-citationImmunotherapy and Combination Strategies in Pancreatic Cancer: Current Status and Emerging Trends
Cheung, P. F., Lutz, M. P., & Siveke, J. T. (2018) · Oncology Research and Treatment · doi:10.1159/000488917 · Cited by 11
Liang, Z., Li, Y., Tian, Y. F., Zhang, H., Cai, W., Chen, A., Chen, L. V., Bao, Y., Xiang, B., Kan, H., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.01.016 · Cited by 11
Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma
Hay, C. A., Sor, R., Flowers, A. J., Clendenin, C. J., & Byrne, K. T. (2019) · Journal of Visualized Experiments · doi:10.3791/60497 · Cited by 11
Self-citationTNF blockade uncouples toxicity from antitumor efficacy induced with CD40 chemoimmunotherapy
Stone, M. L., Lee, J., Herrera, V. M., Graham, K. L., Lee, J. W., Huffman, A. P., Coho, H., Tooker, E., Myers, M. I., Giannone, M. A., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.146314 · Cited by 14
Epigenetic regulation of PD-L1 expression and pancreatic cancer response to checkpoint immunotherapy
Lu, C., & Liu, K. (2017) · Translational Cancer Research · doi:10.21037/tcr.2017.05.32 · Cited by 10
Kurdi, M. E., Mulla, N., Malibary, H. M., Bamaga, A. K., Fadul, M. M., Faizo, E., Hakamy, S., & Baeesa, S. S. (2023) · World Journal of Clinical Oncology · doi:10.5306/wjco.v14.i3.117 · Cited by 11
Guiding immunotherapy combinations: Who gets what?
Ferreira, M., & Choe, J. H. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113962 · Cited by 10
Garnier, J., Turrini, O., Chrétien, A.-S., & Olive, D. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11071948 · Cited by 10
Schmiechen, Z. C., Nanda, H. A., Burrack, A. L., Hickok, G. H., Butler, J. Z., Cruz-Hinojoza, E., Maurice, N. J., Geuenich, M. J., Yu, C., Tsai, A. K., et al. (2025) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-24-0758 · Cited by 9
Zhang, Z., Xiong, Q., Xu, Y., Cai, X., Zhang, L., & Zhu, Q. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12041398 · Cited by 9
The Prospect of Harnessing the Microbiome to Improve Immunotherapeutic Response in Pancreatic Cancer
Rogers, S. C., Charles, A. M., & Thomas, R. M. (2023) · Cancers · doi:10.3390/cancers15245708 · Cited by 9
A New Era: Tumor Microenvironment in Chemoresistance of Pancreatic Cancer
Zhao, X., Li, Z., & Gu, Z. (2022) · Journal of Cancer Science and Clinical Therapeutics · doi:10.26502/jcsct.5079146 · Cited by 9
Diab, M., & El‐Rayes, B. F. (2022) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2022.60 · Cited by 10
Alrifai, D., Sarker, D., & Maher, J. F. (2015) · Immunopharmacology and Immunotoxicology · doi:10.3109/08923973.2015.1100204 · Cited by 10
Animal models of pancreatic cancer and their application in clinical research
Scarlett, C. J., Weidenhofer, J., Colvin, E. K., & Bond, D. R. (2016) · Gastrointestinal Cancer Targets and Therapy · doi:10.2147/gictt.s84531 · Cited by 9
Yoshida, S., Ito, Z., Suka, M., Bito, T., Kan, S., Akasu, T., Saruta, M., Okamoto, M., Kitamura, H., Fujioka, S., et al. (2019) · Cancer Investigation · doi:10.1080/07357907.2019.1661427 · Cited by 9
Mechanisms Underlying Tumor-Associated Macrophages (TAMs)-Facilitated Metastasis
Aleebrahim‐Dehkordi, E., Deravi, N., Fallahi, M. S., & Rezaei, N. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_66-1 · Cited by 8
Bis(benzonitrile) dichloroplatinum (II) interrupts PD-1/PD-L1 interaction by binding to PD-1
Wang, R.-N., Yu, Q., Wang, X.-B., Zhu, D., Li, G., Li, Z.-X., Jiang, W., Li, W., & Dang, Y. (2023) · Acta Pharmacologica Sinica · doi:10.1038/s41401-023-01092-9 · Cited by 8
Roscigno, G., Jacobs, S., Toledo, B., Borea, R., Russo, G., Pepe, F., Serrano, M. J., Calabrò, V., Troncone, G., Giovannoni, R., et al. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.05.003 · Cited by 9
Sheban, F. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1183578 · Cited by 9
Pourali, G., Zafari, N., Velayati, M., Mehrabadi, S., Maftooh, M., Hassanian, S. M., Mobarhan, M. G., Ferns, G. A., Avan, A., & Khazaei, M. (2023) · Current Drug Targets · doi:10.2174/0113894501264450231129042256 · Cited by 9
Challenging Hurdles of Current Targeting in Glioblastoma: A Focus on Immunotherapeutic Strategies
Genoud, V., & Migliorini, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073493 · Cited by 8
A prognostic model for anoikis-related genes in pancreatic cancer
Song, W., Hu, H., Yuan, Z., & Yao, H. (2024) · Scientific Reports · doi:10.1038/s41598-024-65981-7 · Cited by 7
Quijano, E., Martínez‐Saucedo, D., Ianniello, Z., Pinto-Medici, N., Rackear, M., Chen, H., Lola-Pereira, L., Liu, Y., Hegan, D. C., Shan, X., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adk1868 · Cited by 7
Wang, H., Yuan, Y., Lu, C., Zhou, S., Zhang, Y., Zhao, J., Xu, C., Yang, J., Su, H., Li, B., et al. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16358 · Cited by 7
Decreased NSG3 enhances PD-L1 expression by Erk1/2 pathway to promote pancreatic cancer progress.
Xia, X., Li, R., Zhou, P., Xing, Z.-X., Lü, C., Long, Z., Wang, F., & Wang, R. (2021) · PubMed Central · Cited by 7
Spear, S., McNeish, I. A., & Capasso, M. (2019) · Journal of Visualized Experiments · doi:10.3791/60622 · Cited by 7
Mahadevan, K. K., Maldonado, A. S., Li, B., Bickert, A. A., Perdyan, A., Kumbhar, S. V., Piya, S., Sockwell, A. M., Morse, S. J., Arian, K. A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.28.640711 · Cited by 7
Stepanechko, M., Gamache, A., Padilla, F. R., Nemshick, M., Kitelinger, L. E., Conarroe, C. A., DeWitt, M. R., Hossack, J. A., & Bullock, T. N. J. (2025) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2025.3568594 · Cited by 6
Enzler, T., Nguyen, A., Misleh, J. G., Cline, V. J. M., Johns, M., Shumway, N. M., Paulson, S., Siegel, R., Larson, T. G., Messersmith, W. A., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.113950 · Cited by 6
Prognostic value of eight immune gene signatures in pancreatic cancer patients
Wang, W., Xu, Z., Wang, N., Yao, R., Qin, T., Lin, H., & Yue, L. (2021) · BMC Medical Genomics · doi:10.1186/s12920-020-00868-w · Cited by 6
Luo, W., Zheng, L., & Zhang, T. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107199 · Cited by 6
Bai, R.-L., Wang, N.-Y., Zhao, L., Zhang, Y., & Cui, J. (2021) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2021.08.012 · Cited by 6
Stone, M. L., Herrera, V. M., Li, Y., Coho, H., Xue, Y., Graham, K. K., Ratmansky, J., Delman, D., O’Brien, S., & Beatty, G. L. (2025) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-25-0575 · Cited by 5
O'Reilly, E. M., Cabanski, C. R., Lyman, J. P., Wainberg, Z. A., Fisher, G. A., Wolff, R. A., Ko, A. H., O’Hara, M. H., Spencer, C. N., Yu, J. X., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-012864 · Cited by 5
Self-citationNie, H., Wu, Y., Ou, C., & He, X. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.832312 · Cited by 5
Wang, R., Hu, M., Lozzi, I., Jin, C. Z. J., Ma, D., Splith, K., Mengwasser, J., Wolf, V., Feldbrügge, L., Tang, P., et al. (2024) · International Journal of Cancer · doi:10.1002/ijc.35209 · Cited by 5
Zhang, L., Bluth, M. H., & Bhalla, A. (2018) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2018.03.003 · Cited by 5
Gut Microbiome: The Third Musketeer in the Cancer-Immune System Cross-Talk
Sharma, P., Jain, T., Sethi, V., Iyer, S., & Dudeja, V. (2020) · Journal of Pancreatology · doi:10.1097/jp9.0000000000000057 · Cited by 5
Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma
Hay, C. A., Sor, R., Flowers, A. J., Clendenin, C. J., & Byrne, K. T. (2019) · Journal of Visualized Experiments · doi:10.3791/60497-v · Cited by 5
Self-citationLam, C., Lanchoney, O., Maddipatla, V., Markosyan, N., Joshi, N., Hu, X., Ray-Fofana, C., Zeng, S., DeMatteo, R. P., Vonderheide, R. H., et al. (2026) · npj Breast Cancer · doi:10.1038/s41523-025-00889-7 · Cited by 4
Self-citationGriffith, B. D., Kadiyala, P., McGue, J. J., Sun, L., Kumar, A., Espinoza, C. E., Donahue, K. L., Iyer, M. K., Speyer, C. B., Nelson, S., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-0377 · Cited by 5
Zhu, P.-F., Chen, Y.-W., Wang, M., Deng, Y.-Y., Pan, S. L., Chen, Z.-L., & Yang, L. (2021) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001232 · Cited by 5
Dhoundiyal, S., & Alam, A. (2023) · Current Cancer Drug Targets · doi:10.2174/1568009623666230329085618 · Cited by 4
Yin, X., Wang, C., Feng, L., Bai, S.-M., Feng, W., Ouyang, N., Chu, Z., Fan, X., & Qin, Q. (2022) · Cancers · doi:10.3390/cancers14225573 · Cited by 4
Zhang, H., Duan, X.-R., Xing, L.-Y., Jia, Y.-X., Zhou, J., & Ma, J. (2022) · Neoplasma · doi:10.4149/neo_2022_220306n246 · Cited by 4
Extending the Boundaries of Cancer Therapeutic Complexity with Literature Data MiningPreprint
Niezni, D., Taub-Tabib, H., Harris, Y., Sason, H., Amrusi, Y., Azagury, D. M., Avrashami, M., Launer-Wachs, S., Borchardt, J., Kusold, M., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.05.03.490286 · Cited by 4
Agonistic anti-CD40 converts Tregs into Type 1 effectors within the tumor micro-environmentPreprint
Maltez, V. I., Arora, C., Sor, R., Lian, Q., Vonderheide, R. H., Germain, R. N., & Byrne, K. T. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.10.17.512537 · Cited by 3
Self-citationMaltez, V. I., Arora, C., Gribbin, K. P., Caruso, B. P., Haerr, M. E., Sor, R., Lian, Q., Blise, K. E., Sivagnanam, S., Sears, R. C., et al. (2026) · Immunity · doi:10.1016/j.immuni.2026.03.011 · Cited by 3
Self-citationMahadevan, K. K., Maldonado, A. S., Li, B., Bickert, A. A., Perdyan, A., Kumbhar, S. V., Piya, S., Sockwell, A. M., Morse, S. J., Arian, K. A., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-75960-3 · Cited by 12
CD4+ T Cells Mediate MHC-Deficient Tumor Rejection and Endothelial Cell Reprogramming
Kim, S. I., Haerr, M. E., Al-Ghezi, M., Chen, C., Zhang, Y., Phipps, J. L., Arora, C., Gribbin, K. P., Kim, G. T., Markosyan, N., et al. (2025) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-24-1342 · Cited by 3
Self-citationLiang, X., Peng, J., Chen, D., Tang, L. V., Liu, A.-A., Fu, Z., Shi, L., Wang, K., & Shao, C. (2021) · Gland Surgery · doi:10.21037/gs-21-151 · Cited by 3
Interrogating the CD27:CD70 axis in αCD40-dependent control of pancreatic adenocarcinoma
Gamache, A., Conarroe, C. A., Adair, S. J., Bauer, T. W., Padilla, F. R., & Bullock, T. N. J. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1173686 · Cited by 3
Pivotal antitumor role of the immune checkpoint molecule B7-H1 in pancreatic cancer
Bazhin, A. V., von Ahn, K., Fritz, J., Bunge, H., Maier, C., Isayev, O., Neff, F., Siveke, J. T., & Karakhanova, S. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2043037 · Cited by 3
The clinical and prognostic significance of CMTM6/PD-L1 in oncology
Yaseen, M. M., Abuharfeil, N. M., & Darmani, H. (2022) · Clinical & Translational Oncology · doi:10.1007/s12094-022-02811-0 · Cited by 2
Valentine, F. T., Golomb, F. M., Harris, M., & Roses, D. F. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1386827 · Cited by 3
Datta, J., Dai, X., Bianchi, A., Silva, I. D. C., Mehra, S., Garrido, V. T., Lamichhane, P., Singh, S. P., Zhou, Z., Dosch, A. R., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.07.434236 · Cited by 3
Mahadevan, K. K., Dyevoich, A. M., Chen, Y., Li, B., Sugimoto, H., Sockwell, A. M., McAndrews, K. M., Wang, H., Shalapour, S., Watowich, S. S., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.03.05.531191 · Cited by 3
Targeting Tregs in pancreatic ductal adenocarcinoma
Siegel, M., Prabhu, A., Hussain, S., Nwachukwu, D., & Ali, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23523-8.00015-8 · Cited by 2
Subtype-specific NK cell-TAM interactions drive a novel prognostic signature in HNSCC
Zhao, Z., Han, X., Hu, Y., Li, Y., He, Y., Wang, Y., Yao, Y., Li, H., & Wei, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1676878 · Cited by 2
Lin, X.-Y., Zhou, J.-B., Yonemori, K., Zhang, X., Ruan, J., & Jia, Y.-L. (2026) · Genes & Diseases · doi:10.1016/j.gendis.2026.102124 · Cited by 3
Interleukin 6 Drives Durable T Cell-Mediated Immunity to Pancreatic Cancer
Arneson‐Wissink, P. C., Bartlett, A. Q., Mendez, H., Zhu, X., Levasseur, P. R., Diba, P., Murthy, N. T. V., Dickie, J., McWhorter, M., Jozić, A., et al. (2026) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2026.101768 · Cited by 2
Self-citationTargeting PI3Kδ suppresses pancreatic cancer by dual disruption of fibrosis and immune evasion
Garczyk, M., Outeiro-Pinho, G., Pitaktrairat, M., Silva, B. S. S. D., Conza, G. D., Niewola‐Staszkowska, K., Deken, M. A., Johnson, Z., Thapa, A., Fico, F., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117188 · Cited by 2
Liu, W. T., Wang, X., Chen, R., Wen, L., Xiao, A., Wang, W., Zhang, J. I.-X., Liu, M. J., Zhang, X., Liu, X., et al. (2026) · Gut · doi:10.1136/gutjnl-2025-337720 · Cited by 2
Management of Advanced Pancreatic Cancer through Stromal Depletion and Immune Modulation
Liu, T., Cheng, S., Xu, Q., & Wang, Z. P. (2022) · Medicina · doi:10.3390/medicina58091298 · Cited by 2
Extending the boundaries of cancer therapeutic complexity with literature text mining
Niezni, D., Taub-Tabib, H., Harris, Y., Sason, H., Amrusi, Y., Azagury, D. M., Avrashami, M., Launer-Wachs, S., Borchardt, J., Kusold, M., et al. (2023) · Artificial Intelligence in Medicine · doi:10.1016/j.artmed.2023.102681 · Cited by 2
Sokhangouy, S. K., Jamialahmadi, H., Sani, M. S. M., Khalili‐Tanha, G., Rouzbahani, A. K., Mahmoudvand, G., Goudarzi, Z., Fakouri, A., Farokhi, S., Hassanian, S. M., et al. (2024) · Current Cancer Drug Targets · doi:10.2174/0115680096319027240820055043 · Cited by 2
Kobayashi, C., Suzuki‐Imaizumi, M., Sakaguchi, Y., Ishii, T., Adachi, M., Kaneda, A., Ebihara, R., Saito, M., Uemori, T., & Mori, K. (2024) · Cancer Science · doi:10.1111/cas.16366 · Cited by 2
Tontonoz, M. J., & Gee, C. E. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0072 · Cited by 2
Models of intrahepatic cholangiocarcinoma: novel tools and therapeutic applications
Hill, M., Alexander, W. B., & Hezel, A. F. (2018) · Gastrointestinal Cancer Targets and Therapy · doi:10.2147/gictt.s115757 · Cited by 2
The role of the tumor microenvironment in the metastasis of pancreatic cancer and immunotherapy
Tetik, Ş., & Tekkeşin, N. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-819457-7.00005-0 · Cited by 2
Role of the Microbiome in Pancreatic Cancer
Kurtom, S., Sethi, V., & Dudeja, V. (2021) · Springer eBooks · doi:10.1007/978-3-030-53786-9_19 · Cited by 2
High-Affinity Decoy PD-1 Mutant Screened from an Epitope-Specific Cell Library
Liu, H., Qiao, C., Hu, N., Wang, Z., Wang, J., Feng, J., Shen, B., Yuan-fang Ma, A., & Luo, L. (2021) · Engineering · doi:10.1016/j.eng.2020.11.011 · Cited by 2
Emerging agents for metastatic pancreatic cancer: spotlight on early phase clinical trials
Kang, B. W., & Chau, I. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1995354 · Cited by 2
Heery, C. R., Tesfaye, A. A., Weinberg, B., & Marshall, J. L. (2017) · Springer eBooks · doi:10.1007/978-3-319-43063-8_3 · Cited by 4
Obed, A., Siyam, M., Jarrad, A., Abdelhadi, O., Ababneh, M., Annab, H. Z., FÜZESI, L., Bashir, A., & Jarrad, A. (2023) · Journal of Surgical Case Reports · doi:10.1093/jscr/rjac638 · Cited by 2
Sharif, P. M., Khoshbin, A. P., Nasrollahzadeh, E., Keshavarz‐Fathi, M., & Rezaei, N. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-818006-8.00003-7 · Cited by 3
Immunotherapy and checkpoint inhibitors for gliomas
Pearce, C., Chrostek, M. R., Fellows, E. G., Toman, N. G., Tran, S. K., Crane, A. T., & Low, W. C. (2018) · Neuroimmunology and Neuroinflammation · doi:10.20517/2347-8659.2018.46 · Cited by 2
Mehta, A., Hwang, W. L., & Weekes, C. D. (2020) · Annals of Pancreatic Cancer · doi:10.21037/apc-2020-pda-05 · Cited by 2
Javadrashid, D., Baghbanzadeh, A., Hemmat, N., Hajiasgharzadeh, K., Nourbakhsh, N. S., Lotfi, Z., & Baradaran, B. (2021) · Immunology Letters · doi:10.1016/j.imlet.2021.02.009 · Cited by 2
Dharmapuri, S., Cabal, R., Aktürk, G., Ioannou, G., Ozbey, S., Paulsen, J. D., Raina, S., Ang, C., Sarpel, U., Sung, M. W., et al. (2024) · Annals of Translational Medicine · doi:10.21037/atm-23-1928 · Cited by 1
Immunotherapeutic strategies in hepatopancreatobiliary cancers
Salati, M., Rizzo, A., Ricci, A. D., Petrillo, A., & Parisi, A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13376-3.00014-9 · Cited by 1
Alshatti, N., Lemonnier, F., Bachy, E., Lopez, J., Llamas, F., Damotte, D., Burroni, B., Velut, Y., Mauduit, C., de Charette, M., et al. (2025) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2025.101077 · Cited by 1
Minaei, E., Wade, S. J., Penney, C., Ranson, M., Aghmesheh, M., Sluyter, R., & Vine, K. L. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202503780 · Cited by 1
Immediate variations in high‐dimensional circulating immune cells following pancreatectomy
Garnier, J., Palen, A., Durand, X., Ewald, J., Amara, A. B., Rouvière, M. S., Granjeaud, S., Bellan, G., Choisy, B., Verdonk, F., et al. (2025) · Clinical & Translational Immunology · doi:10.1002/cti2.70059 · Cited by 1
Cross‐Cancer Perspectives on CD40 Agonist Therapy: Modulating the Tumor Immune Microenvironment
华旭东, Hua, J., & Wang, Y. (2026) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.70675 · Cited by 1
Tumor Microenvironment: Insights from Multiparametric MRI in Pancreatic Ductal Adenocarcinoma
Paudyal, R., Russell, J., Lekaye, H. C., Deasy, J. O., Humm, J. L., Awais, M., Nadeem, S., Do, R. K. G., O'Reilly, E. M., Schwartz, L. H., et al. (2026) · Cancers · doi:10.3390/cancers18020273 · Cited by 1
Schmiechen, Z. C., Cruz-Hinojoza, E., Hilk, A. L., Ellefson, M. A., Tsai, A. K., Dres, O. M., Kang, L., Geuenich, M. J., Butler, J. Z., Burrack, A. L., et al. (2026) · Science Immunology · doi:10.1126/sciimmunol.adz4302 · Cited by 1
Pilon‐Thomas, S., & Ruffell, B. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.08.012 · Cited by 1
Spear, S., McNeish, I. A., & Capasso, M. (2019) · Journal of Visualized Experiments · doi:10.3791/60622-v · Cited by 1
Two types of biomarker-dependent chemo-immunotherapy for pancreatic cancer?
Melief, C. J. M. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100788 · Cited by 2
Recent Advancement in Drug Targeting Therapies in the Treatment of Pancreatic Cancer
Harwansh, R. K., Hamid, J. A., Wal, P., Deshmukh, R., Patra, P. K., & Gasmi, A. (2025) · Current Pharmaceutical Design · doi:10.2174/0113816128334659241223113743 · Cited by 2
Florou, V., & Wilky, B. A. (2018) · Springer eBooks · doi:10.1007/978-3-319-93530-0_3 · Cited by 1
ESMO 2020 update: Pancreatic cancer
Bergen, E. S. (2021) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-021-00692-7 · Cited by 1
Metadata
- Authors
- Winograd, R., Byrne, K. T., Evans, R. A., Odorizzi, P. M., Meyer, A. R. L., Bajor, D. L., Clendenin, C., Stanger, B. Z., Furth, E. E., Wherry, E. J., & Vonderheide, R. H.
- Affiliations
- University of Pennsylvania (US)
- Corresponding author
- Vonderheide, Robert H.
- ORCID
- Venue
- Cancer Immunology Research
- Published
- 2015-04-01
- Volume
- 3
- Issue
- 4
- Pages
- 399-411
- ISSN
- 2326-6066 (ISSN-L)
- 2326-6074
- PMC
- PMC4390506
- OpenAlex
- W2132290857
- Cited by
- 459
- References
- 87
- Citations by year
- 2026: 18 · 2025: 24 · 2024: 27 · 2023: 44 · 2022: 42 · 2021: 78 · 2020: 53 · 2019: 51 · 2018: 40 · 2017: 37 · 2016: 33 · 2015: 11
- FWCI
- 17.76
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cancer Immunology Research (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- University of Pennsylvania
- York University
- National Heart, Lung, and Blood Institute (T32HL007775, T32HL007439)
- National Cancer Institute (T32CA009140, R01CA169123, P30CA016520)
- National Institute of Allergy and Infectious Diseases (P01AI112521, U19AI082630)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- pancreatic ductal adenocarcinoma, anti-PD-1 therapy, CTLA-4 blockade, immune checkpoint inhibitors, treatment resistance, PD-L1, tumor microenvironment, T cell immunity, combination chemotherapy, tumor immunogenicity, immunological memory, genetically engineered mouse models
- MeSH terms
- Gemcitabine, Animals, Antibodies, Monoclonal, Antimetabolites, Antineoplastic, Combined Modality Therapy, Deoxycytidine, Female, Genetic Engineering, Humans, Immune Tolerance, Immunity, Cellular, Interferon-gamma, Lymphocyte Activation, Mice, Inbred C57BL, Pancreatic Neoplasms, T-Lymphocyte Subsets, CD40 Antigens, Carcinoma, Pancreatic Ductal, Xenograft Model Antitumor Assays, Cell Line, Tumor, Tumor Microenvironment, B7-H1 Antigen, CTLA-4 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
